Kazia Therapeutics - Edison Group

Overview
Price performance
Financials
Research
Thematics

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

View More

Healthcare |
Flash note

01.02.23

Kazia Therapeutics — Reinvestment period with increased R&D focus

Healthcare |
ADR Flash

19.12.22

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Healthcare |
Update

07.12.22

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Healthcare |
Flash note

01.11.22

Kazia Therapeutics — Q123 cash flows in line with our estimates

Balance Sheet

Forecast net debt (US$m)

6

Forecast gearing ratio (%)

224

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	7.1	28.2	(77.5)
Relative	3.2	19.1	(78.4)
52 week high/low	US$6.0/US$0.5

Financials

Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical efforts towards exploring the applicability and efficacy of paxalisib in non-central nervous system (CNS) oncology indications such as melanoma and other solid tumors, including breast cancer. Post-period, Kazia announced a A$4.5m fund-raise through a two-stage private placement of 40.9m new shares (25.4m unconditional shares and 15.5m conditional shares) at A$0.11 per share. Management intends to use the proceeds to support its development programs (including the paxalisib GBM AGILE study due to readout in H2 CY23) and working capital requirements. The period-end net cash balance stood at A$4.4m and this, along with the A$4.5m fund-raise, should provide headroom into H2 CY23, based on current burn rates.

Y/E Jun	Revenue (US$m)	EBITDA (US$m)	PBT (US$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2021A	10.7	(3.1)	(3.1)	(25.09)	N/A	N/A
2022A	0.0	(14.9)	(14.9)	(110.57)	N/A	N/A
2023E	0.0	(19.0)	(19.0)	(111.41)	N/A	N/A
2024E	10.8	(17.2)	(17.2)	(82.84)	N/A	N/A

edison tv

Healthcare

11.05.22

EVT801, Kazia’s second programme, and capital markets

edison tv

Healthcare

10.05.22

Paxalisib: Beyond glioblastoma and commercial opportunity

edison tv

Healthcare

09.05.22

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

ADR Update

Healthcare

28.03.22

Kazia Therapeutics — Several upcoming catalysts

edison tv

Healthcare

10.02.22

Kazia Therapeutics: Edison Open House Healthcare 2022

edison tv

Healthcare

25.10.21

Kazia Therapeutics – introducing novel asset EVT-801

ADR Update

Healthcare

14.10.21

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Update

Healthcare

13.10.21

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

edison tv

Healthcare

19.05.21

Kazia Therapeutics – overview and update with CEO James Garner

ADR Update

Healthcare

20.04.21

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Update

Healthcare

19.04.21

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

ADR Update

Healthcare

30.03.21

Kazia Therapeutics — Paxalisib Chinese rights licensed

Update

Healthcare

29.03.21

Kazia Therapeutics — Paxalisib Chinese rights licensed

ADR Update

Healthcare

08.03.21

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Update

Healthcare

01.03.21

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

edison tv

Healthcare

03.02.21

Kazia Therapeutics – Edison Open House interview

ADR Update

Healthcare

11.12.20

Kazia Therapeutics — Cantrixil final Phase I data reported

Update

Healthcare

10.12.20

Kazia Therapeutics — Cantrixil final Phase I data reported

ADR Update

Healthcare

02.12.20

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Update

Healthcare

24.11.20

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Initiation

Healthcare

28.08.20

Kazia Therapeutics — Bringing a vetted drug class to the brain

Update

Healthcare

31.03.20

Kazia Therapeutics — Paxalisib trial still on track for H220 start

ADR Update

Healthcare

13.01.20

Kazia Therapeutics — An agile pivot

Update

Healthcare

13.01.20

Kazia Therapeutics — An agile pivot

ADR Update

Healthcare

02.12.19

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

edison tv

Healthcare

25.11.19

Executive interview – Kazia Therapeutics

Update

Healthcare

25.11.19

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Update

Healthcare

05.09.19

Kazia Therapeutics — GDC-0084 gets a fifth collaboration

ADR Outlook

Healthcare

21.06.19

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Outlook

Healthcare

21.06.19

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

ADR Update

Healthcare

01.04.19

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Update

Healthcare

29.03.19

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

ADR Update

Healthcare

29.10.18

Kazia Therapeutics — New indications for GDC-0084

Update

Healthcare

29.10.18

Kazia Therapeutics — New indications for GDC-0084

ADR Update

Healthcare

19.09.18

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Update

Healthcare

19.09.18

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Outlook

Healthcare

13.05.18

Kazia Therapeutics — GDC-0084 Phase II underway

ADR Outlook

Healthcare

11.05.18

Kazia Therapeutics — GDC-0084 Phase II underway

Update

Healthcare

11.09.17

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Update

Healthcare

11.09.17

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Outlook

Healthcare

25.05.17

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Outlook

Healthcare

22.05.17

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Update

Healthcare

31.10.16

Novogen — Update 31 October 2016

ADR Update

Healthcare

11.05.16

Novogen — Update 11 May 2016

Update

Healthcare

09.05.16

Novogen — Update 9 May 2016